Search - tctmd.com

Displaying 181 - 200 of 1375

Sort: Relevancy | Date

Three Common Biomarkers Closely Tied to Women’s 30-Year Risk of CV Events

News Conference News ESC 2024

Three Common Biomarkers Closely Tied to Women’s 30-Year Risk of CV Events

August 31, 2024

BedMed and BedMed-Frail randomized controlled trials

Presentation ESC 2024

BedMed and BedMed-Frail randomized controlled trials

Presenter: Scott Garrison

August 31, 2024

QUADRO Phase III Study: Efficacy and Safety of the new Quadruple SPC Perindopril/Indapamide/Amlodipine/Bisoprolol in Patients with Resistant Hypertension

Presentation ESC 2024

QUADRO Phase III Study: Efficacy and Safety of the new Quadruple SPC Perindopril/Indapamide/Amlodipine/Bisoprolol in Patients with Resistant Hypertension

Presenter: Stefano Taddei

August 31, 2024

New BedMed Data Confirm Antihypertensives Can Be Taken Any Time of Day

News Conference News ESC 2024

New BedMed Data Confirm Antihypertensives Can Be Taken Any Time of Day

Yael L. Maxwell

August 31, 2024

Polypills Show Promise in Diverse Hypertensive Patient Groups

News Conference News ESC 2024

Polypills Show Promise in Diverse Hypertensive Patient Groups

August 31, 2024

Stop-or-Not It’s OK to Tailor RAS Inhibitor Use Around Noncardiac Surgery

News Conference News ESC 2024

Stop-or-Not: It’s OK to Tailor RAS Inhibitor Use Around Noncardiac Surgery

August 30, 2024

ABYSS: Safety Signal Seen When Beta-blockers Stopped in Post-MI Patients

News Conference News ESC 2024

ABYSS: Safety Signal Seen When Beta-blockers Stopped in Post-MI Patients

Michael O'Riordan

August 30, 2024

Study Supports Cost-effectiveness of Renal Denervation for Hypertension

News Daily News

Study Supports Cost-effectiveness of Renal Denervation for Hypertension

August 23, 2024

New Data Reassure on Rivaroxaban’s Role in Frail PAD Patients

News Daily News

New Data Reassure on Rivaroxaban’s Role in Frail PAD Patients

August 19, 2024

Tirzepatide Provides Sustained BP Reduction in Overweight Adults

News Daily News

Tirzepatide Provides Sustained BP Reduction in Overweight Adults

August 15, 2024

Obstacles Abound for Treating Severe BP: Some Clues for Care Lie in EHRs

News Daily News

Obstacles Abound for Treating Severe BP: Some Clues for Care Lie in EHRs

August 08, 2024

Payment Parity for Telehealth Linked to Better BP Treatment

News Daily News

Payment Parity for Telehealth Linked to Better BP Treatment

Michael O'Riordan

August 07, 2024

PREVENT Risk Calculator Means Fewer Patients on Statins, Antihypertensives

News Daily News

PREVENT Risk Calculator Means Fewer Patients on Statins, Antihypertensives

Michael O'Riordan

August 02, 2024

August 2024 Dispatch for the CV Team

News Opinion CV Team Dispatch

August 2024 Dispatch for the CV Team

August 01, 2024

Olympic Hearts: Screening for CVD Among Team USA’s Athletes

News Opinion Editor's Corner

Olympic Hearts: Screening for CVD Among Team USA’s Athletes

Michael O'Riordan

July 31, 2024

AAA-Related Mortality Rates Decline, With Reductions Seen in All Groups

News Daily News

AAA-Related Mortality Rates Decline, With Reductions Seen in All Groups

Michael O'Riordan

July 29, 2024

Improved Lipids With Gastric Bypass Linked to Surgery Itself, Not Weight Loss

News Daily News

Improved Lipids With Gastric Bypass Linked to Surgery Itself, Not Weight Loss

Michael O'Riordan

July 23, 2024

Coronary Calcium Scoring May Help Get Semaglutide to Highest-Risk Patients

News Conference News SCCT 2024

Coronary Calcium Scoring May Help Get Semaglutide to Highest-Risk Patients

July 22, 2024

Incidental CAC Tied to Worse Outcomes in Systemic Inflammatory Diseases

News Conference News SCCT 2024

Incidental CAC Tied to Worse Outcomes in Systemic Inflammatory Diseases

July 21, 2024

Apixaban May Have Advantages in Patients With Liver Cirrhosis and AF

News Daily News

Apixaban May Have Advantages in Patients With Liver Cirrhosis and AF

Michael O'Riordan

July 09, 2024

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.